The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer

Author： Abern Michael R.   Terris Martha K.   Aronson William J.   Kane Christopher J.   Amling Christopher L.   Cooperberg Matthew R.   Freedland Stephen J.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|11|1656-1662

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.11, 2014-06, pp. : 1656-1662

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Staging, cytoreduction and chemotherapy improve long-term outcomes in patients with ovarian cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 8, 2006-08 ,pp. : 10-13

Adis International

Access to resources Recommend Favorite

Long-term goserelin does not deprive prostate cancer patients

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer

By Kumar Aalok   Kennecke Hagen F.   Renouf Daniel J.   Lim Howard J.   Gill Sharlene   Woods Ryan   Speers Caroline   Cheung Winson Y.  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 527-534

Blackwell Publishing

Access to resources Recommend Favorite

Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection

By Mackiewicz Andrzej   Mackiewicz Jacek   Wysocki Piotr J.   Wiznerowicz Maciej   Kapcinska Malgorzata   Laciak Maria   Rose-John Stefan   Izycki Dariusz   Burzykowski Tomasz   Karczewska-Dzionk Aldona  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 6, 2012-06 ,pp. : 773-783

Informa Healthcare

Access to resources Recommend Favorite

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer

By Roach Mack  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1620-1629

Blackwell Publishing

Access to resources Recommend Favorite